Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Medigene Ag

Mor Research Applications Ltd.

Deutsches Krebsforschungszentrum

Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts

Deutsches Krebsforschungszentrum Stifung Des Offentlichen Rechts

Peter Altevogt

Gerhard Moldenhauer

Daniela Kelm

Yi Li

Mina Fogel

Ulrich Moebius

Sandra Lüttgau

Sandra Luettgau

Susanne Sebens

Heiner Schaefer

Frank Brietling

Achim Krueger

Frank Breitling

Achim Krüger

Silke Baerreiter

Silke Bärreiter

John Hazin

Ulrich Möbius

Silke Wolterink

Sascha Keller

Heiner Schäfer

The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules.

Binding molecules, especially antibodies, binding to L1CAM (CD171)

The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.

Treatment of tumors using specific anti-L1 antibody

The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.

Method for prenatal diagnosis

Described is a pharmaceutical composition comprising a compound(s) interfering with the biological activity of L1 and/or ADAM10 or their expression. Also described is the use of said compound(s) for the prevention/treatment of carcinomas like ovarian and endometrial carcinoma. Finally, the diagnosis of highly malignant forms of carcinomas which is based on the determination of the activity/expression of L1 and/or ADAM10 is described.

Inhibitors of L1 and ADAM10 for the treatment of carcinomas

A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.

Diagnostic and therapeutic methods based on the L1 adhesion molecule for ovarian and endometrial tumors

Growing community of inventors

Neckargemünd, Germany

Peter Altevogt